Glaucoma

Ribonucleic acid-based therapy for glaucoma:  LncRNA SNHG1  increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 14/March/2019, 6.58 pm
Ribonucleic acid-based therapy for glaucoma:  LncRNA SNHG1  increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 14/March/2019, 6.58 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the The Jackson Laboratory, Bar Harbor, ME 04609, USA; Department of Ophthalmology, Tufts University of Medicine, Boston, MA 02111, USA; The Howard Hughes…

read more

Ribonucleic acid-based therapy for glaucoma:  LncRNA TUG1  increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 13/March/2018, 5.26 am
Ribonucleic acid-based therapy for glaucoma:  LncRNA TUG1  increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 13/March/2018, 5.26 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the The Jackson Laboratory, Bar Harbor, ME 04609, USA; Department of Ophthalmology, Tufts University of Medicine, Boston, MA 02111, USA; The Howard Hughes…

read more

Cholecalciferol-based therapy for glaucoma:  1α, 25 (OH)2D/Cholecalciferol/Calcitriol  increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 26/February/2019, 8.50 am
Cholecalciferol-based therapy for glaucoma:  1α, 25 (OH)2D/Cholecalciferol/Calcitriol  increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 26/February/2019, 8.50 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the The Jackson Laboratory, Bar Harbor, ME 04609, USA; Department of Ophthalmology, Tufts University of Medicine, Boston, MA 02111, USA; The Howard Hughes…

read more

Lipid-lowering agent Fenofibrate comes to the rescue of glaucoma: Fenofibrate (trade name: Tricor,  Fenacor, Feno-TG, Fenobate, Fenocor, Fenofibric, Fenolip and others), a drug used to lower cholesterol and triglycerides,  increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 26/February/2019, 12.14 am
Lipid-lowering agent Fenofibrate comes to the rescue of glaucoma: Fenofibrate (trade name: Tricor,  Fenacor, Feno-TG, Fenobate, Fenocor, Fenofibric, Fenolip and others), a drug used to lower cholesterol and triglycerides,  increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 26/February/2019, 12.14 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the The Jackson Laboratory, Bar Harbor, ME 04609, USA; Department of Ophthalmology, Tufts University of Medicine, Boston, MA 02111, USA; The Howard Hughes…

read more

Molecular therapy for glaucoma: Trimetazidine (TMZ), the drug used in the treatment of angina pectoris,  increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 16/January/2018, 11.27 pm
Molecular therapy for glaucoma: Trimetazidine (TMZ), the drug used in the treatment of angina pectoris,  increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 16/January/2018, 11.27 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the The Jackson Laboratory, Bar Harbor, ME 04609, USA; Department of Ophthalmology, Tufts University of Medicine, Boston, MA 02111, USA; The Howard Hughes…

read more

Molecular therapy for glaucoma: Ulinastatin (trade name: Miraclid, Ulinase, U-Tryp,Bikunin and Urinastatin), an urinary trypsin inhibitor used in the treatment of  acute/chronic pancreatitis, burns and others,  increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 15/January/2018, 11.36 pm
Molecular therapy for glaucoma: Ulinastatin (trade name: Miraclid, Ulinase, U-Tryp,Bikunin and Urinastatin), an urinary trypsin inhibitor used in the treatment of  acute/chronic pancreatitis, burns and others,  increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 15/January/2018, 11.36 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the The Jackson Laboratory, Bar Harbor, ME 04609, USA; Department of Ophthalmology, Tufts University of Medicine, Boston, MA 02111, USA; The Howard Hughes…

read more
Start Typing